Avexitide

Exendin (9-39), exendin 9-39 amide, Ex9-39

Metabolic & weight

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

1What it is

Exendin (9-39) is what you get when the first eight amino acids are removed from exendin-4, the lizard-saliva peptide that became the drug exenatide. Those eight residues are what activate the GLP-1 receptor; without them the fragment still binds the receptor but blocks it. Physiologists have used exendin (9-39) since the 1990s as the standard tool to prove that GLP-1 matters for a given effect: infuse it, and whatever GLP-1 was doing stops.

Avexitide is the pharmaceutical name for the same peptide, developed for post-bariatric hypoglycaemia (PBH). After gastric bypass, food reaches the lower gut fast and triggers a very large GLP-1 release, which drives an insulin surge and dangerous low blood sugar an hour or two after eating. There is no approved treatment. Avexitide was developed by a small company and then acquired; it is now in late-stage development with Breakthrough Therapy and Orphan Drug status in the US.

2How it's thought to work

Competitive antagonism of the GLP-1 receptor on pancreatic beta cells reduces glucose-dependent insulin secretion after meals.

In PBH this lowers the post-meal insulin peak and the depth of the subsequent glucose fall, without affecting fasting glucose in most studies.

It also blocks GLP-1 effects on gastric emptying and glucagon, which may contribute by restoring the counter-regulatory glucagon response.

A GLP-1 receptor antagonist — the mirror image of the agonists. Where too much insulin is the problem, as in post-bariatric hypoglycaemia, blocking the receptor reduces insulin release so glucose stops falling through the floor.Schematic — not to scale

3What the research shows

Post-bariatric hypoglycaemia

LUCIDITY, a Phase 3 trial of 78 adults at 21 US sites randomised 3:2 to avexitide 90 mg once daily or placebo, reported in August 2026 that avexitide reduced composite Level 2 and Level 3 hypoglycaemic events by 55% versus placebo over 16 weeks (p < 0.00001), with all secondary endpoints met, including continuous glucose monitor-defined events and independently adjudicated severe (Level 3) events. Body weight did not change in either arm. These are company-reported topline results and have not yet been published in a journal; the grade should be re-checked on publication †.

Graded A (small)

Phase 2

PREVENT, a randomised, placebo-controlled crossover trial in 18 participants, found that 30 mg twice daily and 60 mg once daily reduced post-meal glucose nadir and insulin peak and reduced hypoglycaemic events (Craig 2021, Diabetes Care). An earlier Phase 2 showed similar effects with 4 weeks of dosing (Craig 2018, Diabetologia) †. [1][2]

Mechanistic infusion studies

Intravenous exendin (9-39) in people with PBH normalised post-meal glucose and insulin, establishing GLP-1 excess as the driver (Salehi 2014, Gastroenterology; Craig 2017, Diabetologia). [3][4]

Congenital hyperinsulinism

Small studies in children and adults with congenital hyperinsulinism reported raised fasting glucose and fewer hypoglycaemic episodes with exendin (9-39) infusion (Calabria 2012, Diabetes). An orphan programme exists †. [5]

4Reported side effects and interactions

Literature-reported

In LUCIDITY the most common events were diarrhoea, injection-site erythema and injection-site bruising; adverse events were mostly mild to moderate and no serious event was judged related to treatment. Phase 2 trials reported injection-site reactions, headache, nausea and, uncommonly, hyperglycaemia. Weight was unchanged.

Community-reported

essentially none documented.

Theoretical. blocking GLP-1 could worsen glucose control in people with diabetes; raise appetite; or interact with GLP-1 (it would cancel them). None of these has been a problem in the PBH trials, where participants did not have diabetes.

Interactions. direct pharmacological antagonism of GLP-1 receptor agonists (semaglutide, liraglutide, exenatide and others) and of DPP-4 inhibitors' GLP-1-mediated effects.

Markers researchers commonly monitor

From the trial protocols:

Marker	Why it's watched
Continuous glucose monitoring	time below 54 mg/dL (3.0 mmol/L) and number of Level 2/3 events are the primary measures.
Self-monitored blood glucose with symptom diary	defines Level 2 (<54 mg/dL) and Level 3 (requiring assistance) events.
Post-meal insulin and glucose (mixed-meal tolerance test)	mechanistic markers in research settings.
HbA1c	to confirm no drift towards hyperglycaemia with GLP-1 blockade.
Body weight	unchanged in trials, but relevant given the mechanism.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Investigational formulation supplied to trial sites; details of presentation are not public. Research-grade exendin (9-39) is used in laboratories as a peptide. No validated self-administration guidance exists and the calculator does not apply.

6Commonly studied alongside

Dietary modification and acarbose (the usual first-line PBH measures), continuous glucose monitoring, and as a mechanistic blocker alongside GLP-1 agonists in physiology research. Conceptually the mirror image of exenatide and semaglutide (#3).

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Investigational. Breakthrough Therapy and Orphan Drug designations for PBH; NDA submission planned by end of 2026 with potential launch 2027 †
European Union	Not authorised; orphan designation †
United Kingdom	Not licensed
Australia	Not approved
South Africa	Not registered
Sport (WADA)	Not on the Prohibited List; not a performance-enhancing class

8Open questions

Will the 16-week LUCIDITY benefit persist over years, and does GLP-1 receptor blockade eventually blunt satiety or raise weight?
Benefit in other hyperinsulinaemic hypoglycaemia states (congenital hyperinsulinism, post-fundoplication dumping).
Whether a longer-acting formulation can achieve once-weekly dosing.

9References

1Craig CM et al. (2021). Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia (PREVENT). Diabetes Obes Metab [verify journal]. PubMed
2Craig CM et al. (2018). Subcutaneous exendin (9-39) effectively treats post-bariatric hypoglycaemia. Diabetologia [verify]. PubMed
3Salehi M, Gastaldelli A, D'Alessio DA (2014). Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology. PubMed · DOI
4Craig CM et al. (2017). Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia. PubMed · DOI
5Calabria AC et al. (2012). GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. PubMed · DOI
6Company announcement of LUCIDITY Phase 3 topline results, August 2026 [verify primary source; journal publication pending]. PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.